SUCCESSFUL SCREENING definition

SUCCESSFUL SCREENING when used in conjunction with the phrase "Taisho Activated Receptor" means that the results of the Screening has been positive whereby at least one molecule that has been contacted with the Taisho Activated Receptor reduces the Measured Response of the Taisho Activated Receptor by at least two (2) standard deviations from the mean response of a screening plate that includes that compound.
SUCCESSFUL SCREENING when used in conjunction with the phrase "Fujisawa Selected Receptor" means that the results of the Screening has been positive whereby at least one molecule that has been contacted with the Fujisawa Activated Receptor reduces the Measured Response of the Fujisawa Activated Receptor by at least two (2) standard deviations from the mean response of a screening plate that includes that compound.
SUCCESSFUL SCREENING means that the results of the Screening have been

Examples of SUCCESSFUL SCREENING in a sentence

  • A DIFFERENT FORM OF INJURY PREVENTION: SUCCESSFUL SCREENING AND REFERRAL FOR HIV AND HEPATITIS C IN A TRAUMA POPULATIONPage 129 Benjamin White, MD Medical University of South Carolina 8:00am - 8:20am33.

  • SCREENING OF FILM 10 WEEK > 4 MONTH OF RELEASESCREENING OF HPCL SELECTED HINDI, ENGLISH OR REGIONAL FILMS IN DIGITAL FORMAT ALONG WITH PROVIDING MOVIE SERVER AND DIGITAL PROJECTOR (WITH LENS) AND ANY OTHER ACCESSORIES REQUIRED FOR SUCCESSFUL SCREENING OF MOVIES ON PER MOVIE SCREENING BASIS.


More Definitions of SUCCESSFUL SCREENING

SUCCESSFUL SCREENING means that the results of the Screening have been positive whereby at least one molecule from ICI Library Ingredients that has been Screened reduces or enhances the Measured Response of the CART Activated Receptor by at least [******************] from the mean response of a screening plate that includes that compound.
SUCCESSFUL SCREENING when used in conjunction with the phrase "TaiGen Activated Receptor" means that the results of the Screening has been positive whereby at least one molecule that has been contacted with the TaiGen Activated Receptor reduces the Measured Response of the TaiGen Activated Receptor by at least [*********** **********] from the mean response of a screening plate that includes that compound.
SUCCESSFUL SCREENING when used in conjunction with the phrase "Activated Orphan Receptor" means that the results of the Screening has been positive whereby at least one molecule within Library Compounds that has been contacted with the Activated Orphan Receptor reduces the Measured Response of the Activated Orphan Receptor by at least two (2) standard deviations from the mean response of a screening plate that includes that compound.

Related to SUCCESSFUL SCREENING

  • Successful Completion means that in the reasonable opinion of the Customer, Deliverables completed by the Supplier are fit for purpose, completed on time and otherwise meet all the criteria defined under this Contract;

  • Successful Vendor means the organization or person with whom the order is placed or who is contracted to execute the work as detailed in the bid.

  • Successful Applicant means an “employee applicant” or “applicant” who has been offered employment within this Bargaining Unit by the Employer.

  • Successful Bid means the Bid of the Successful Bidder for acquisition of the Corporate Debtor on Going Concern basis as declared by the Liquidator as per this Process Memorandum;

  • Successful Syndication shall have the meaning given to such term in the Fee Letter.

  • Successful Proponent means a Proponent who the City may award the agreement to, as a result of this RFP document.

  • Successful Proposer means any Proposer selected by the University to receive an Award as a result of this RFP and to enter into a Contract to provide the University with the products or services sought by this RFP.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Successful Bidder” or “Successful E-Auction Process Participant means, the Qualified Bidder whose bid is approved and who is declared successful by the Liquidator at the end of the determined auction phase.C. INTRODUCTION

  • Phase III Trial means a human Clinical Trial of the Licensed Product, which trial is designed (a) to establish that the Licensed Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c) consistent with 21 CFR § 312.21(c).

  • Successful Bidder As defined in Section 7.01(c).

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Successful Bidder(s) means the bidder(s) to whom work in this tender is awarded.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Supplier/ Successful or Selected bidder means the person, private or government entity, or a combination of the above, whose Bid to perform the Contract has been accepted by the Purchaser and is named as such in the Agreement, and includes the legal successors or permitted assigns of the successful/ selected bidder.

  • Targeted Unsuccessful Security Incident means an Unsuccessful Security Incident that appears to be an attempt to obtain unauthorized Access, Use, Disclosure, modification or destruction of the Covered Entity’s Electronic PHI.